Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma
Abstract Background To explore the prognosis predicting ability of the combined factors, Epstein–Barr virus DNA change level (EBVCL) and tumor volume reduction ratio (TVRR) after inductive chemotherapy (IC), in locally advanced nasopharyngeal carcinoma (LANPC). Methods From 2010 to 2018, 299 LANPC p...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4964 |
| _version_ | 1811176396157878272 |
|---|---|
| author | Zhong‐zheng Xiang Tao He Yuan‐yuan Zeng Fang Liu Bian‐fei Shao Tian Yang Jia‐chun Ma Xi‐ran Wang Si‐ting Yu Lei Liu |
| author_facet | Zhong‐zheng Xiang Tao He Yuan‐yuan Zeng Fang Liu Bian‐fei Shao Tian Yang Jia‐chun Ma Xi‐ran Wang Si‐ting Yu Lei Liu |
| author_sort | Zhong‐zheng Xiang |
| collection | DOAJ |
| description | Abstract Background To explore the prognosis predicting ability of the combined factors, Epstein–Barr virus DNA change level (EBVCL) and tumor volume reduction ratio (TVRR) after inductive chemotherapy (IC), in locally advanced nasopharyngeal carcinoma (LANPC). Methods From 2010 to 2018, 299 LANPC patients were included in this retrospective study. Receiver operating characteristic (ROC) curve analysis was performed to acquire the best critical values. According to the best critical values of EBVCL and TVRR, patients were stratified into low‐ and high‐risk groups. Kaplan–Meier and ROC curve analyses were utilized to verify the prognostic ability of the new predictor (EBVCL+TVRR). The prognostic values among EBVCL+TVRR, EBVCL, TVRR, TNM stage, and the RECIST 1.1 criteria were compared by ROC curve. The primary end points were overall survival (OS), progression‐free survival (PFS), distant metastasis‐free survival (DMFS), and locoregional failure‐free survival (LRFFS). Results ROC curve analyses of TVRR on three‐year survival showed the best critical values of TVRR was 32.72% for OS, 30.21% for PFS and LRFFS, 29.87% for DMFS. The best critical value of EBVCL was 127 copies/ml for OS, and 87.7 copies/ml for PFS, DMFS, and LRFFS. The three‐year OS, PFS, DMFS, and LRFFS for low‐ and high‐risk groups were 97.7% versus 78.3% (hazard ratio [HR] = 0.2398; 95% confidence interval [CI]: 0.1277–0.4502; p < 0.0001), 91.1% versus 60.9% (HR = 0.3294; 95% CI: 0.2050–0.5292; p < 0.0001), 94.2% versus 68.7% (HR = 0.2413; 95% CI: 0.1284–0.4535; p < 0.0001) and 97.8% versus 77.9% (HR = 0.3078; 95% CI: 0.1700–0.5573; p = 0.0001), respectively. The maximal area under ROC curve of EBVCL+TVRR, EBVCL, TVRR, TNM stage, and RECIST 1.1 criteria for three‐year OS was 0.829, 0.750, 0.711, 0.555, and 0.605, respectively. Conclusion The new‐developed indicator (EBVCL+TVRR) could better predict the LANPC patient's survival after IC compared with TNM stage system or RECIST 1.1 criteria. |
| first_indexed | 2024-04-10T19:51:53Z |
| format | Article |
| id | doaj.art-8f40cb12f9e64c728f86bcf748b46afb |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T19:51:53Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8f40cb12f9e64c728f86bcf748b46afb2023-01-28T05:30:04ZengWileyCancer Medicine2045-76342023-01-011221102111310.1002/cam4.4964Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinomaZhong‐zheng Xiang0Tao He1Yuan‐yuan Zeng2Fang Liu3Bian‐fei Shao4Tian Yang5Jia‐chun Ma6Xi‐ran Wang7Si‐ting Yu8Lei Liu9Department of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaDepartment of Head and Neck Oncology Cancer Center, West China Hospital of Sichuan University Chengdu Sichuan P.R. ChinaAbstract Background To explore the prognosis predicting ability of the combined factors, Epstein–Barr virus DNA change level (EBVCL) and tumor volume reduction ratio (TVRR) after inductive chemotherapy (IC), in locally advanced nasopharyngeal carcinoma (LANPC). Methods From 2010 to 2018, 299 LANPC patients were included in this retrospective study. Receiver operating characteristic (ROC) curve analysis was performed to acquire the best critical values. According to the best critical values of EBVCL and TVRR, patients were stratified into low‐ and high‐risk groups. Kaplan–Meier and ROC curve analyses were utilized to verify the prognostic ability of the new predictor (EBVCL+TVRR). The prognostic values among EBVCL+TVRR, EBVCL, TVRR, TNM stage, and the RECIST 1.1 criteria were compared by ROC curve. The primary end points were overall survival (OS), progression‐free survival (PFS), distant metastasis‐free survival (DMFS), and locoregional failure‐free survival (LRFFS). Results ROC curve analyses of TVRR on three‐year survival showed the best critical values of TVRR was 32.72% for OS, 30.21% for PFS and LRFFS, 29.87% for DMFS. The best critical value of EBVCL was 127 copies/ml for OS, and 87.7 copies/ml for PFS, DMFS, and LRFFS. The three‐year OS, PFS, DMFS, and LRFFS for low‐ and high‐risk groups were 97.7% versus 78.3% (hazard ratio [HR] = 0.2398; 95% confidence interval [CI]: 0.1277–0.4502; p < 0.0001), 91.1% versus 60.9% (HR = 0.3294; 95% CI: 0.2050–0.5292; p < 0.0001), 94.2% versus 68.7% (HR = 0.2413; 95% CI: 0.1284–0.4535; p < 0.0001) and 97.8% versus 77.9% (HR = 0.3078; 95% CI: 0.1700–0.5573; p = 0.0001), respectively. The maximal area under ROC curve of EBVCL+TVRR, EBVCL, TVRR, TNM stage, and RECIST 1.1 criteria for three‐year OS was 0.829, 0.750, 0.711, 0.555, and 0.605, respectively. Conclusion The new‐developed indicator (EBVCL+TVRR) could better predict the LANPC patient's survival after IC compared with TNM stage system or RECIST 1.1 criteria.https://doi.org/10.1002/cam4.4964Epstein–Barr virus DNA change levelinductive chemotherapynasopharyngeal carcinomaprognosistumor volume reduction ratio |
| spellingShingle | Zhong‐zheng Xiang Tao He Yuan‐yuan Zeng Fang Liu Bian‐fei Shao Tian Yang Jia‐chun Ma Xi‐ran Wang Si‐ting Yu Lei Liu Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma Cancer Medicine Epstein–Barr virus DNA change level inductive chemotherapy nasopharyngeal carcinoma prognosis tumor volume reduction ratio |
| title | Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| title_full | Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| title_fullStr | Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| title_full_unstemmed | Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| title_short | Epstein–Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| title_sort | epstein barr virus dna change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma |
| topic | Epstein–Barr virus DNA change level inductive chemotherapy nasopharyngeal carcinoma prognosis tumor volume reduction ratio |
| url | https://doi.org/10.1002/cam4.4964 |
| work_keys_str_mv | AT zhongzhengxiang epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT taohe epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT yuanyuanzeng epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT fangliu epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT bianfeishao epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT tianyang epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT jiachunma epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT xiranwang epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT sitingyu epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma AT leiliu epsteinbarrvirusdnachangelevelcombinedwithtumorvolumereductionratioafterinductivechemotherapyasabetterprognosticpredictorinlocallyadvancednasopharyngealcarcinoma |